Search company, investor...

Predict your next investment

Private Equity
FINANCE | Investment Firms & Funds
3i.com

Investments

1343

Funds

38

Partners & Customers

6

Service Providers

3

About 3i Group

3i (LSE: III) is a multinational private equity and venture capital company. 3i invests in across a wide range of sectors, with specialist global teams in Oil, Gas and Power, Technology, Media, Business Services, Healthcare, Consumer, General Industrial, and Financial Services.

Headquarters Location

16 Palace Street

London, England, SW1E 5JD,

United Kingdom

+44 (0) 20 7975 3131

Want to inform investors similar to 3i Group about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Expert Collections containing 3i Group

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find 3i Group in 1 Expert Collection, including Vitamin & Supplement Startups.

V

Vitamin & Supplement Startups

237 items

Latest 3i Group News

Bionter AG. (5/2/23). "Press Release: Ten23 Health, a Swiss-based CDMO and Bionter, a Premium Supplier of Analytical Ttesting Te...

May 13, 2023

Organisation Index term Non-destructive particle counting – ten23 health and Bionter collaborate to improve testing of particulates in sterile products. ten23 health, a global contract development and manufacturing organization, and Bionter, a premium supplier of analytical testing technology, announced today their collaboration to advance innovative testing methods of particulate matter. > Bionter has launched EVE, a fully automated particle testing system, to assess sub-visible particulate contamination for parenteral drug applications based on light obscuration. > ten23 health has been running customer samples on an EVE system and is also acting as an application center for Bionter. > Due to the non-destructive nature of Bionter’s EVE particle testing equipment, the same sample can be further analyzed with orthogonal analyzing methods whilst minimizing sample volume needed. > The Bionter installation complements ten23 health’s comprehensive method and equipment panel for the characterization and assessment of aggregates and particulates, including light obscuration, automated flow imaging, nano-tracking analysis (NTA), Dynamic or Static light scattering stand-alone or coupled with chromatographic separation techniques, as well as identification of visible particles by spectroscopic methods. Dr. Björn Boll, Senior Director for Particle Characterization and Drug Product Design at ten23 health commented: “We are excited to offer this new technology to our customers. It offers several advantages over established methods that could improve workflows due to automation and reduction of sample consumption.” Dr. Tobias Werk, CEO of Bionter, stated: “We strive to develop innovative solutions for our customers. The partnership with ten23 gives us insight into the daily challenges of biologics analytics and allows and inspires us to further tailor our solutions to the true needs.” About ten23 health ten23 health®, located in Basel, Switzerland, is the human-centric and sustainable strategic partner of choice for the pharmaceutical industry and biotech start-ups: we develop, manufacture, and test modern medicines. We support our clients in developing differentiated, stable, usable, and safe injectable treatment options for patients. Our second site, located in Visp, Switzerland, is a world leader in the sterile production of complex pharmaceutical dosage forms and a wholly owned subsidiary of ten23 health. ten23 health combines the latest scientific findings with proven and tested worldclass industry and regulatory expertise to forge new paths for supporting clients. We provide our innovative services in a fair and sustainable manner, respecting people’s health and the future of our planet. ten23 health is solidly financed through the long-term commitment of 3i Group, an internationally reputable equity partner. About Bionter Bionter is a Swiss-based Biotech start-up. Since the foundation in 2020, Bionter has established successful prototype testing with 4 global Pharma companies, received successful seed funding from a US investor and launched their first product in Europe and the US. The team has significant experience in particle analytics as well as the commercialization of biotech products. Bionter’s first product, EVE, is a fully automated particulate matter detection system, that works non-destructive with the sample used and is fully compliant with current regulations. Bionter is a premium supplier of analytical testing solutions and contributes to the benefit of people’s health by helping pharma companies and their service providers to bring drugs faster and safer to the market. Media contacts: Bionter: Angelika Schrems, angelika.schrems@bionter.com; +41 77 266 53 96 3i Group: Kathryn van der Kroft, Kathryn.VanDerKroft@3i.com; +44 20 7975 3021

3i Group Investments

1,343 Investments

3i Group has made 1,343 investments. Their latest investment was in VakantieDiscounter as part of their Private Equity on July 7, 2022.

CBI Logo

3i Group Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

7/11/2022

Private Equity

VakantieDiscounter

Yes

1

6/16/2022

Private Equity - II

Digital Barriers

Yes

1

6/7/2022

Private Equity

Xsuite

Yes

2

3/18/2022

Private Equity - II

Subscribe to see more

Subscribe to see more

10

1/27/2022

Private Equity

Subscribe to see more

Subscribe to see more

10

Date

7/11/2022

6/16/2022

6/7/2022

3/18/2022

1/27/2022

Round

Private Equity

Private Equity - II

Private Equity

Private Equity - II

Private Equity

Company

VakantieDiscounter

Digital Barriers

Xsuite

Subscribe to see more

Subscribe to see more

Amount

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

2

10

10

3i Group Acquisitions

192 Acquisitions

3i Group acquired 192 companies. Their latest acquisition was Konges Slojd on June 20, 2022.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

6/20/2022

$99M

Acq - Fin

2

12/1/2021

$99M

Acq - Fin

1

11/9/2020

$99M

Acq - Fin

2

9/22/2020

Private Equity

Subscribe to see more

$99M

$99M

Subscribe to see more

10

7/28/2020

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/20/2022

12/1/2021

11/9/2020

9/22/2020

7/28/2020

Investment Stage

Private Equity

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$99M

Note

Acq - Fin

Acq - Fin

Acq - Fin

Subscribe to see more

Subscribe to see more

Sources

2

1

2

10

10

3i Group Fund History

38 Fund Histories

3i Group has 38 funds, including 3i Venice.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/19/2019

3i Venice

Diversified Private Equity

Open

$425.24M

1

4/16/2018

3i European Operational Projects Fund

REAL Assets

Closed

$529.28M

1

4/11/2018

European Operational Projects Fund

$563.8M

1

9/15/2016

Harvest XV CLO

Subscribe to see more

Subscribe to see more

$99M

10

5/13/2016

Harvest CLO XV

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

12/19/2019

4/16/2018

4/11/2018

9/15/2016

5/13/2016

Fund

3i Venice

3i European Operational Projects Fund

European Operational Projects Fund

Harvest XV CLO

Harvest CLO XV

Fund Type

Diversified Private Equity

REAL Assets

Subscribe to see more

Subscribe to see more

Status

Open

Closed

Subscribe to see more

Subscribe to see more

Amount

$425.24M

$529.28M

$563.8M

$99M

$99M

Sources

1

1

1

10

10

3i Group Partners & Customers

6 Partners and customers

3i Group has 6 strategic partners and customers. 3i Group recently partnered with AutoRek on November 11, 2017.

Date

Type

Business Partner

Country

News Snippet

Sources

11/8/2017

Vendor

United Kingdom

3i Selects AutoRek to Enhance Controls and Governance of Asset Records - bobsguide.com

Today , AutoRek , the leading software solutions provider for financial controls , data management and regulatory reporting , announces that 3i Group plc , an international investment manager , has selected AutoRek to enhance controls and automation of asset records to support its continued growth .

1

6/12/2012

Vendor

Canada

Subscribe to see more

Subscribe to see more

10

2/27/2012

Partner

Spain

Subscribe to see more

Subscribe to see more

10

2/23/2010

Partner

Sweden

Subscribe to see more

Subscribe to see more

10

8/28/2008

Partner

Belgium

Subscribe to see more

Subscribe to see more

10

Date

11/8/2017

6/12/2012

2/27/2012

2/23/2010

8/28/2008

Type

Vendor

Vendor

Partner

Partner

Partner

Business Partner

Country

United Kingdom

Canada

Spain

Sweden

Belgium

News Snippet

3i Selects AutoRek to Enhance Controls and Governance of Asset Records - bobsguide.com

Today , AutoRek , the leading software solutions provider for financial controls , data management and regulatory reporting , announces that 3i Group plc , an international investment manager , has selected AutoRek to enhance controls and automation of asset records to support its continued growth .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

3i Group Service Providers

9 Service Providers

3i Group has 9 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Acq - Fin, Acq - Fin - II, and Private Equity

Investment Bank

Financial Advisor

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Subscribe to see more

Associated Rounds

Acq - Fin, Acq - Fin - II, and Private Equity

Subscribe to see more

Subscribe to see more

Provider Type

Investment Bank

Subscribe to see more

Subscribe to see more

Service Type

Financial Advisor

Subscribe to see more

Subscribe to see more

Partnership data by VentureSource

3i Group Team

69 Team Members

3i Group has 69 team members, including current Chief Executive Officer, Simon Borrows.

Name

Work History

Title

Status

Simon Borrows

Kester Capital

Chief Executive Officer

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Simon Borrows

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Kester Capital

Title

Chief Executive Officer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.